# University of Washington: Phase 2 study closed enrollment, 33 enrolled (Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | University of Washington |
| Sponsor type | Academic and hospital |
| Study | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma |
| NCT ID | NCT05455697 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma |
| Intervention types | procedure, drug, biological, other |
| Target enrollment | 33 |
| Site countries | United States |
| Posted | 2022-07-13 |
| Planned start | 2023-01-26 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05455697). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.